Results 51 to 60 of about 1,800 (153)
Pre‐treatment DPYD and UGT1A1 genotyping is increasingly used to prevent fluoropyrimidine‐ and irinotecan‐related toxicity, but variant‐specific real‐world effects remain unclear. In an unselected cohort of cancer patients with actionable genotypes, genotype‐driven dosing improved safety while preserving treatment exposure in high‐risk DPYD c.1905+1G>A
Martina Gambron +12 more
wiley +1 more source
Background Immune checkpoint inhibitor (ICI) or irinotecan-based chemotherapy is frequently used after failure of second-line paclitaxel plus ramucirumab treatment for patients with locally advanced unresectable or metastatic advanced gastric cancer (AGC)
Sung Hee Lim +20 more
doaj +1 more source
We have recently demonstrated that the oral bioavailability of irinotecan (80 mg/kg) can be increased at least 7-fold by co-administration of the P-gp blocker verapamil (25 mg/kg, Oral).
Tripta Garg +3 more
doaj +1 more source
Irinotecan is widely used in the treatment of metastatic colorectal cancer (mCRC) despite its severe toxicities. Toxicity is often associated with the UGT1A1*28/*28 genotype.
Pau Riera +9 more
doaj +1 more source
Clinical Translation of Patient‐Derived Organoids: Perspectives for Personalized Therapy in Cancer
ABSTRACT Patient‐derived organoids (PDO) are accelerating precision medicine. These biological platforms allow for the autologous in vitro expansion of material from cancer patients in a considerably short period of time. These three‐dimensional models can faithfully recapitulate aspects of tissue heterogeneity, architecture, and relevant cellular ...
Haiyan Yue +6 more
wiley +1 more source
Advances in Immunological Combination Therapy for Colorectal Cancer
Review the progress of combined immunotherapy for colorectal cancer. ABSTRACT Immune checkpoint inhibitors (ICIs) have been utilized extensively and shown to be therapeutically beneficial in the treatment of solid tumors in recent years. Nonetheless, considerable heterogeneity in Colorectal cancer (CRC) requires careful consideration.
Jiayue Wu +7 more
wiley +1 more source
Background/Objectives: Irinotecan is used in monotherapy or combined with other drugs for treating different cancer streams. SN-38, the active metabolite of irinotecan, is 70% inactivated by the uridine diphosphate (UDP) glucuronosyltransferase family 1 ...
Xando Díaz-Villamarín +9 more
doaj +1 more source
Microbiome—pancreatic cancer crosstalk: From tumor biology to therapeutic intervention
The intratumoral microbiome acts as a critical regulator in pancreatic cancer progression and therapeutic resistance. This comprehensive review delineates the origins of pancreatic microbes, elucidates their multifaceted mechanisms in driving immune suppression, metabolic reprogramming, and stromal desmoplasia, and highlights the clinical potential of ...
Yuqin Xie +12 more
wiley +1 more source
Sonographic Diagnosis of an Intercostal Artery Pseudoaneurysm: A Case Report and Literature Review
A 63‐year‐old male presented to the emergency department after being found unconscious during a welfare check. Following a prolonged three‐month hospital admission, the patient developed left flank pain. Spectral Doppler ultrasound revealed a large isoechoic lesion with layering echoes, and spectral Doppler demonstrated bidirectional flow.
Aaditya P. Singh, Peter R. Coombs
wiley +1 more source
RT‐immunotherapy synergy for thoracic tumors relies on precise target delineation to protect immune components. IFI, reduced volumes, and optimized positioning minimize damage, while multimodal imaging, DL, PBT, and FLASH‐RT enhance control. These innovations shift RT to an immune‐centric model, improving lung and esophageal cancer outcomes.
Xiaoying Chen +3 more
wiley +1 more source

